[Image: masthead]



Outside NA: 001-209-417-3722

24-HOUR MH HOTLINE: 800-644-9737
Outside NA: 001-209-417-3722


Caroff SN. Drug-induced hyperthermic syndromes in psychiatry. Clin Psychopharmacol Neurosci, 2021;19(1):1-11.

Misawa, F., Fujii, Y., Takeuchi, H. Can a 4-Month Tolerability Assessment With Paliperidone Palmitate 1-Monthly Prevent Neuroleptic Malignant Syndrome Associated With the 3-Monthly? Analysis Based on a Spontaneous Reporting System Database in Japan. J Clin Psychopharmacol 2021 [Epub 2021/02/05].

Caroff SN, Jain R, Morley JF.  Revisiting amantadine as a treatment for drug-induced movement disorders.  Ann Clin Psychiatry 2020;32(3):198-208.

Caroff SN. Risk of Neuroleptic Malignant Syndrome with Vesicular Monoamine Transporter Inhibitors. Clin Psychopharmacol Neurosci, 2020;18:322-326.

Guinart, D., Misawa, F., Rubio, J. M., Pereira, J., Sharma, H., Schoretsanitis, G., Kane, J. M., Correll, C. U. Outcomes of Neuroleptic Malignant Syndrome With Depot Versus Oral Antipsychotics: A Systematic Review and Pooled, Patient-Level Analysis of 662 Case Reports. J Clin Psychiatry 2020;82: [Epub 2020/11/26].

Kruijt, N., van den Bersselaar, L. R., Wijma, J., Verbeeck, W., Coenen, M. J. H., Neville, J., Snoeck, M., Kamsteeg, E. J., Jungbluth, H., Kramers, C., Voermans, N. C. HyperCKemia and rhabdomyolysis in the neuroleptic malignant and serotonin syndromes: A literature review. Neuromuscul Disord 2020;30: 949-958.

Kuhlwilm, L.,Schönfeldt-Lecuona, C., Gahr, M., Connemann, B. J., Keller, F., Sartorius, A. The Neuroleptic Malignant Syndrome - A systematic case series analysis focusing on therapy regimes and outcome. Acta Psychiatr Scand 2020 [Epub 2020/07/14].

Sato, I., Onishi, H., Kawanishi, C., Yamada, S., Ishida, M., Kawakami, K. Neuroleptic malignant syndrome in patients with cancer: a systematic review. BMJ Support Palliat Care 2020 [Epub 2020/05/18].

Morcos, N., Rosinski, A., Maixner, D. F. Electroconvulsive Therapy for Neuroleptic Malignant Syndrome: A Case Series. 2019;35: 225-230.

Prakash, S., Rathore, C., Rana, K. K., Dave, A., Joshi, H., Patel, J. Refining the Clinical Features of Serotonin Syndrome: A Prospective Observational Study of 45 Patients. Ann Indian Acad Neurol 2019;22:52-60.

Schonfeldt-Lecuona, C., Kuhlwilm, L., Cronemeyer, M., Neu, P., Connemann, B. J., Gahr, M., Sartorius, A., Muhlbauer, V. Treatment of the Neuroleptic Malignant Syndrome in International Therapy Guidelines: a Comparative Analysis. Pharmacopsychiatry 2019 [Epub 2019/12/11].

VR Velamoor VR, Cernovsky Z. Age and Gender Specific Patterns of the Neuroleptic Malignant Syndrome. Archives of Psychiatry and Behavioural Sciences. 2019;2:22-26

Huang MW, Gibson RC, Moberg PJ, Caroff SN. Antipsychotics for schizophrenia spectrum disorders with catatonic symptoms (protocol). Cochrane Database of Systematic Reviews 2018, Issue 10. Art. No.: CD013100. DOI: 10.1002/14651858.CD013100.

Velamoor R, Pulagam G. Geriatric Psychopharmacology: A complex case of psychosis complicated by Neuroleptic Malignant Syndrome and Metabolic Syndrome.  Complex Clinical Conundrums in Psychiatry. From Theory to Clinical Management. Edited by K Shivakumar and S Amanullah Springer Press 2018, P 23-37.

Caroff SN.  Parkinsonism-hyperthermia syndrome and deep brain stimulation.  Can J Anesth, [Epub ahead of print], February, 2017; 2017;64:675-676.

Caroff SN, Mann SC, Campbell EC: NMDAR-encephalitis and risk of neuroleptic malignant syndrome. Pediatric Neurology 2017;66:e3.

Velamoor, R. Neuroleptic malignant syndrome: A neuro-psychiatric emergency: Recognition, prevention, and management. Asian J Psychiatr 2017;29: 106-109.

Gurrera RJ, Mortillaro G, Velamoor V, Caroff SN: A validation study of the international consensus diagnostic criteria for neuroleptic malignant syndrome. J Clin Psychopharmacol 2017;37:67-71.

Gurrera RJ. A systematic review of sex and age factors in neuroleptic malignant syndrome diagnosis
Frequency. Acta Psychiatr Scand 2017: 135: 398–408.

Ghaziuddin, N., Hendriks, M., Patel, P., Wachtel, L. E., Dhossche, D. M. Neuroleptic Malignant Syndrome/Malignant Catatonia in Child Psychiatry: Literature Review and a Case Series. J Child Adolesc Psychopharmacol 2017;27:359-365.

Caroff SN, Campbell EC: Drug-induced extrapyramidal syndromes; implications for contemporary practice. Psychiatr Clin N Am 2016:39;391–411.

Caroff SN, Campbell EC: Drug-induced extrapyramidal syndromes; implications for contemporary practice. Psychiatr Clin N Am 2016:39;391–411.

Modi, S., Dharaiya, D., Schultz, L., Varelas, P. Neuroleptic Malignant Syndrome: Complications, Outcomes, and Mortality. Neurocrit Care 2016;24: 97-103.

Belvederi Murri, M, Guaglianone, A, Bugliani, M, Calcagno, P, Respino, M, Serafini, G, Innamorati, M, Pompili, M, Amore, M. Second-generation antipsychotics and neuroleptic malignant syndrome: systematic review and case report analysis. Drugs R D 2015;15:45-62.

Mann, S.C., Caroff, S.C., Ungvari, G.S., Campbell, E.C.: Catatonia, malignant catatonia, and neuroleptic malignant syndrome. Current Psychiatry Reviews 9: 111-119, 2013

Gurrera RJ, Caroff SN, Cohen A, Carroll BT, DeRoos F, Francis A, Frucht S, MD, Gupta S, Levenson JT, Mahmood A,  Mann SC, Policastro MA, Rosebush P, Rosenberg H, Sachdev PS, Trollor JN, Velamoor VR, Watson CB, Wilkinson JR. An international consensus study of neuroleptic malignant syndrome diagnostic criteria using the Delphi method. J Clin Psychiatry, 2011;72:1222-1228.

Strawn JR, Keck PE Jr, Caroff SN. Neuroleptic malignant syndrome.  Am J Psychiatry,  2007; 164:870-876

Kawanishi C, Kishada I, Furuno T, Kato D, Bertilsson L. Pharmacogenetic aspects of neuroleptic malignant syndrome. Current Pharmacogenomics 2006;4:113-119.

The mission of MHAUS is to promote optimum care and
scientific understanding of MH and related disorders.